Literature DB >> 15572262

Tools for measuring clinical effectiveness.

Dieter Naber1, Antonio Vita.   

Abstract

Efficacy studies fail to consider the multiple aspects of schizophrenia that determine the overall clinical effectiveness of treatment. We address this shortcoming by proposing definitions of six schizophrenia outcome domains which we believe contribute to clinical effectiveness: symptoms of disease, tolerability, everyday functioning, subjective well-being, family/career burden, and treatment adherence. Numerous specialised rating scales are in widespread use; however, these only assess specific aspects of schizophrenia within individual domains and are of limited use for measuring clinical effectiveness. New rating instruments that measure treatment outcomes across all six domains of schizophrenia need to be developed. One such scale is the revised Global Outcome Assessment of Life in Schizophrenia (GOALS) scale. We propose that further development of this scale should include validation in long-term studies, incorporation of the patient perspective of treatment within assessments, and education of clinicians on how to score this scale. If this approach to evaluating treatment outcomes is adopted, clinicians will be better placed to differentiate therapeutic interventions on the basis of clinical effectiveness.

Entities:  

Mesh:

Year:  2004        PMID: 15572262     DOI: 10.1016/j.euroneuro.2004.08.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  3 in total

1.  Is there a linear relationship between the Brief Psychiatric Rating Scale and the Clinical Global Impression-Schizophrenia scale? A retrospective analysis.

Authors:  Jitsuki Sawamura; Shigeru Morishita; Jun Ishigooka
Journal:  BMC Psychiatry       Date:  2010-12-07       Impact factor: 3.630

2.  Autistic Symptoms in Schizophrenia: Impact on Internalized Stigma, Well-Being, Clinical and Functional Characteristics.

Authors:  Stefano Barlati; Gabriele Nibbio; Donato Morena; Paolo Cacciani; Paola Corsini; Alessandra Mosca; Giacomo Deste; Vivian Accardo; Valentina Regina; Jacopo Lisoni; Cesare Turrina; Paolo Valsecchi; Antonio Vita
Journal:  Front Psychiatry       Date:  2022-03-30       Impact factor: 4.157

3.  Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.

Authors:  Andrea de Bartolomeis; Andrea Fagiolini; Marco Vaggi; Claudio Vampini
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-11       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.